Surgical treatment and prognosis of 51 cases of splenic marginal lymphoma
10.3760/cma.j.cn113855-20230412-00189
- VernacularTitle:脾边缘区淋巴瘤51例的手术治疗及预后分析
- Author:
Xinrong QU
1
;
Zuyin LI
;
Delin MA
;
Runze ZHU
;
Jie GAO
Author Information
1. 北京大学人民医院肝胆外科，北京 100044
- Keywords:
Lymphoma,B cell,marginal zone;
Splenic neoplasms;
Splenectomy;
Treatment;
Prognosis
- From:
Chinese Journal of General Surgery
2023;38(8):600-604
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical characteristics, treatment and prognosis of splenic marginal zone lymphoma.Methods:The clinical data of 51 patients with splenic marginal zone lymphoma who underwent surgical treatment at Department of Hepatobiliary in Peking University People's Hosipital from Dec 2009 to Oct 2022 were retrospectively analyzed.Results:The patients 's average age was 60.5±11.8 years old, and the ratio of male to female rate was about 1:1. As of the last follow-up date of Feb 28, 2023, 8 patients died of the primary lymphoma and 14 patients suffered from disease progression. The 5-year progression free survival rate was 68%, and the overall survival rate was 79%. Univariate analysis showed that age ≥65 years old, decreased preoperative albumin, increased bilirubin level, and increased lactate dehydrogenase bode ill for overall survival time, but none of them were independent risk factors; Age ≥65 years old and diffuse large B cell transformation were independent risk factors.Conclusions:Surgery combined with comprehensive treatment which contained rituximab is currently the main treatment method. Splenectomy remains an important treatment and diagnostic method for patients with obvious symptoms or persistent unrelieved blood count abnormalities and unexplained splenomegaly. Advanced age, elevated bilirubin and lactate dehydrogenase, decreased albumin, and diffuse large B cell transformation, it may indicate poor prognosis.
